Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
pharmaphorum
SEPTEMBER 16, 2022
The question now is how to tailor dosage even more closely to fit patients’ needs. “[L]ess He has been a research fellow at Harvard Medical School, Boston, the University of California, San Francisco, and University Spital Zürich, Switzerland, where his research focused on atopic dermatitis and the complexity of the skin barrier.
89 
Let's personalize your content